Orchestra BioMed Holdings, Inc.
NASDAQ: OBIO0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- David Hochman
- Employees
- 70
- Headquarters
- New Hope, United States
- IPO year
- 2020
- Market cap
- $238.3M
- Website
- https://orchestrabiomed.com
Loading OBIO…
Loading profile data…Frequently asked questions about OBIO
What does Orchestra BioMed Holdings, Inc. (OBIO) do?
Orchestra BioMed Holdings, Inc. operates as an innovative company in the biomedical sector. Its leading product candidates are BackBeat Cardiac Neuromodulation Therapy (CNT), designed to manage hypertension, and the Virtue Sirolimus AngioInfusion Balloon (SAB), aimed at treating atherosclerotic artery disease. The company's offerings also encomp...
Where does OBIO trade?
Orchestra BioMed Holdings, Inc. (OBIO) trades on the NASDAQ Global Market.
What sector is OBIO in?
Orchestra BioMed Holdings, Inc. (OBIO) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Orchestra BioMed Holdings, Inc.?
David Hochman is the chief executive officer of Orchestra BioMed Holdings, Inc. (OBIO).
Where is Orchestra BioMed Holdings, Inc. headquartered?
Orchestra BioMed Holdings, Inc. is headquartered in United States.
Does OBIO pay a dividend?
Orchestra BioMed Holdings, Inc. (OBIO) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did OBIO go public?
Orchestra BioMed Holdings, Inc. (OBIO) completed its initial public offering in 2020.